Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 10, 2011, Pages 1206-1214

  Dige, Anders ^a   Hvas, Christian Lodberg ^a   Deleuran, Bent ^b   Kelsen, Jens ^a,c   Bendix Struve, Mia ^a   Dahlerup, Jens Frederik ^a   Agnholt, Jørgen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c RANDERS REGIONAL HOSPITAL   (Denmark)

Author keywords

Adalimumab; Crohn's disease; FOXP3 protein; Regulatory T lymphocytes

Indexed keywords

ADALIMUMAB; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; INFLAMMATION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CD4 LYMPHOCYTE COUNT; CROHN DISEASE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 80052906811     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.603157     Document Type: Article

References (27)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007;369:1627-40. (Pubitemid 46722636)
3. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005;128:1868-78. (Pubitemid 40824698)
4. Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt- Weber CB, Banham AH, et al. Characterization of FOXP3 +CD4+ regulatory T cells in Crohns disease. Clin Immunol 2007;125:281-90. (Pubitemid 350123608)
5. Di SA, Biancheri P, Piconese S, Rosado MM, Ardizzone S, Rovedatti L, et al. Peripheral regulatory T cells and serum transforming growth factor-beta: Relationship with clinical response to infliximab in Crohns disease. Inflamm Bowel Dis 2010;16:1891-7.
6. Hvas CL, Kelsen J, Agnholt J, Dige A, Christensen LA, Dahlerup JF. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohns disease. Autoimmunity 2010;43:325-33.
7. Kelsen J, Agnholt J, Hoffmann HJ, Romer JL, Hvas CL, Dahlerup JF. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohns disease. Clin Exp Immunol 2005;141: 549-57. (Pubitemid 41075880)
8. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004;173: 3119-30. (Pubitemid 39142018)
9. Faubion WA, De Jong YP, Molina AA, Ji H, Clarke K, Wang B, et al. Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology 2004;126:1759-70. (Pubitemid 38736341)
10. Kaser A, Blumberg RS. The other way round: colitis regulates regulatory T cells. Gastroenterology 2004;126: 1903-6. (Pubitemid 38736355)
11. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007;204:33-9. (Pubitemid 46148753)
12. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-85. (Pubitemid 39031247)
13. Li Z, Arijs I, De HG, Vermeire S, Noman M, Bullens D, et al. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm Bowel Dis 2010;16:1299-310.
14. Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohns disease. Immunology 2008;125:178-83.
15. Boschetti G, Nancey S, Sardi F, Roblin X, Flourie B, Kaiserlian D. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:160-70.
16. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345-54. (Pubitemid 46523383)
17. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69:3995-4000.
18. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-7.
19. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factorbeta dependent but does not confer a regulatory phenotype. Blood 2007;110:2983-90. (Pubitemid 350006952)
20. Aerts NE, Dombrecht EJ, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell Immunol 2008;251:109-15.
21. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohns disease activity index. National Cooperative Crohns Disease Study. Gastroenterology 1976;70: 439-44.
22. Best WR. Predicting the Crohns disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12: 304-10.
23. Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert- Margolis V, et al. Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom 2009;76:69-78.
24. Law JP, Hirschkorn DF, Owen RE, Biswas HH, Norris PJ, Lanteri MC. The importance of Foxp3 antibody and fixation/permeabilization buffer combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytometry A 2009; 75:1040-50.
25. Presicce P, Moreno-Fernandez ME, Lages CS, Orsborn KI, Chougnet CA. Association of two clones allows for optimal detection of human FOXP3. Cytometry A 2010;77:571-9.
26. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, et al. Generation of potent and stable human CD4+ T regulatory cells by activationindependent expression of FOXP3. Mol Ther 2008;16: 194-202.
27. Hardenberg G, Steiner TS, Levings MK. Environmental influences on T regulatory cells in inflammatory bowel disease. Semin Immunol 2011;23:130-8.